Aim: Despite recent advances in the treatment of ovarian cancer, recurrence of the disease is still frequent. This study evaluated whether multiple lines of chemotherapy have impact on overall survival (OS), progression free survival (PFS) or on treatment free intervals (TFIs) after serial chemotherapy lines in recurrent settings. Methods: A total of 189 patients with ovarian cancer (including fallopian tube and primary peritoneal cancer), who were treated in Kuopio University Hospital in Finland during 2009-2014, were enrolled. The medical files of these patients were retrospectively reviewed. Results: Median OS and PFS were significantly higher at the time of the first relapse compared to subsequent relapses (p < 0.001). TFIs shortened significantly after the first relapse (p < 0.001). The differences in TFIs were also seen when comparing platinum sensitive, semi-sensitive and platinum resistant patients. The total amount of TFI times during the whole follow-up time was significantly re duced in those patients that received at least one form of aggressive care at the end of life (p = 0.004). Conclusions: Ovarian cancer patients received often mul tiple lines of chemotherapy. TFIs after subsequent chemotherapy lines de creased during the disease course. More efforts should be taken to avoid unne cessary and ineffective treatments especially in recurrent phase of the disease.
KeywordsOvarian CancerChemotherapyTreatment Free IntervalOverall SurvivalProgression Free SurvivalAggressive Care
Engholm, G., Ferlay, J., Christensen, N., Hansen, H., Hertzum-Larsen, R., Johannesen, T., et al. (2017) Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.0 (20.12.2017). Association of the Nordic Cancer Registries. Danish Cancer Society. http://www.ancr.nu
Timmermans, M., Sonke, G.S., Van de Vijver, K.K., van der Aa, M.A. and Kruitwagen, R.F.P.M. (2018) No Improvement in Long-Term Survival for Epithelial Ovarian Cancer Patients: A Population-Based Study between 1989 and 2014 in the Netherlands. European Journal of Cancer, 88, 31-37. https://doi.org/10.1016/j.ejca.2017.10.030
Eng, K.H., Hanlon, B.M., Bradley, W.H. and Szender, J.B. (2015) Prognostic Factors Modifying the Treatment-Free Interval in Recurrent Ovarian Cancer. Gynecologic Oncology, 139, 228-235. https://doi.org/10.1016/j.ygyno.2015.09.011
Bailey, C.H., Jameson, G., Sima, C., Fleck, S., White, E., Von Hoff, D.D., et al. (2012) Progression-Free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. Journal of Cancer, 3, 7-13. https://doi.org/10.7150/jca.3.7
Wilson, M.K., Pujade-Lauraine, E., Aoki, D., Mirza, M.R., Lorusso, D., Oza, A.M., et al. (2017) 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease. Annals of Oncology, 28, 727-732. https://doi.org/10.1093/annonc/mdw663
Yoshihama, T., Chiyoda, T., Kataoka, F., Nomura, H., Iguchi, Y., Hashimoto, S., et al. (2015) Effectiveness of Third-Line Chemotherapy in Recurrent Ovarian Cancer Patients. European Journal of Gynaecological Oncology, 36, 424-427.
Sallinen, H., Rintanen, V., Keski-Nisula, L. and Anttila, M. (2021) Evaluation of Ovarian Cancer Care at the End of Life in a Single Tertiary Hospital. Journal of Cancer Therapy, 12, 86-96. https://doi.org/10.4236/jct.2021.122010
Anonymous National Voluntary Consensus Standards for Quality of Cancer Care. http://www.qualityforum.org/Publications/2009/05/National_Voluntary_Consensus_Standards_for_Quality_of_Cancer_Care.aspx
The ICON and AGO Collaborators (2003) Paclitaxel plus Platinum-Based Chemotherapy versus Conventional Platinum-Based Chemotherapy in Women with Relapsed Ovarian Cancer: The ICON4/AGO-OVAR-2.2 Trial. The Lancet, 361, 2099-2106. https://doi.org/10.1016/S0140-6736(03)13718-X
Mahner, S., Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell’Anna, T., et al. (2015) Carboplatin and Pegylated Liposomal Doxorubicin versus Carboplatin and Paclitaxel in Very Platinum-Sensitive Ovarian Cancer Patients: Results from a Subset Analysis of the CALYPSO Phase III Trial. European Journal of Cancer, 51, 352-358. https://doi.org/10.1016/j.ejca.2014.11.017
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., et al., (2014) Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in a Randomised Phase 2 Trial. The Lancet Oncology, 15, 852-861. https://doi.org/10.1016/S1470-2045(14)70228-1
Hoskins, P.J. and Le, N. (2005) Identifying Patients Unlikely to Benefit from Further Chemotherapy: A Descriptive Study of Outcome at Each Relapse in Ovarian Cancer. Gynecologic Oncology, 97, 862-869. https://doi.org/10.1016/j.ygyno.2005.03.022
Hanker, L.C., Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., et al. (2012) The Impact of Second to Sixth Line Therapy on Survival of Relapsed Ovarian Cancer after Primary Taxane/Platinum-Based Therapy. Annals of Oncology, 23, 2605-2612. https://doi.org/10.1093/annonc/mds203
Roncolato, F.T., O’Connell, R.L., Joly, F., Lanceley, A., Hilpert, F,. Buizen, L., et al. (2020) Predictors of Progression Free Survival, Overall Survival and Early Cessation of Chemotherapy in Women with Potentially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Starting Third or Subsequent Line(≥3) Chemotherapy—The GCIG Symptom Benefit Study (SBS). Gynecologic Oncology, 156, 45-53. https://doi.org/10.1016/j.ygyno.2019.10.001
Acaster, S., Gaugris, S., Velikova, G., Yong, K. and Lloyd, A. (2013) Impact of the Treatment-Free Interval on Health-Related Quality of Life in Patients with Multiple Myeloma: A UK Cross-Sectional Survey. Supportive Care in Cancer, 21, 599-607. https://doi.org/10.1007/s00520-012-1548-y
Friedlander, L.M., Stockler, T.M., O’connell, T.R., Voysey, T.M., Oza, T.A., Gillies, T.K., et al. (2014) Symptom Burden and Outcomes of Patients with Platinum Resistant/Refractory Recurrent Ovarian Cancer: A Reality Check: Results of Stage 1 of the Gynecologic Cancer Intergroup Symptom Benefit Study. International Journal of Gynecological Cancer, 24, 857-864. https://doi.org/10.1097/IGC.0000000000000147
Pfisterer, J., Shannon, C.M., Baumann, K., Rau, J., Harter, P., Joly, F., et al. (2020) Bevacizumab and Platinum-Based Combinations for Recurrent Ovarian Cancer: A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 21, 699-709. https://doi.org/10.1016/S1470-2045(20)30142-X
Mirza, M.R., Monk, B.J., Herrstedt, J., Oza, A.M., Mahner, S., Redondo, A., et al. (2016) Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The New England Journal of Medicine, 375, 2154-2164. https://doi.org/10.1056/NEJMoa1611310
Pujade-Lauraine, E., Ledermann, J.A., Selle, F., Gebski, V., Penson, R.T., Oza, A.M., et al. (2017) Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 18, 1274-1284. https://doi.org/10.1016/S1470-2045(17)30469-2
Matulonis, U.A., Shapira-Frommer, R., Santin, A.D., Lisyanskaya, A.S., Pignata, S., Vergote, I., et al. (2019) Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase II KEYNOTE-100 Study. Annals of Oncology, 30, 1080-1087. https://doi.org/10.1093/annonc/mdz135